Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences

被引:229
作者
Rauch, U [1 ]
Osende, JI [1 ]
Fuster, V [1 ]
Badimon, JJ [1 ]
Fayad, Z [1 ]
Chesebro, JH [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
关键词
D O I
10.7326/0003-4819-134-3-200102060-00014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To describe the characteristics of thrombus formation on atherosclerotic plaques, the clinical expression of atherothrombosis in Vascular disease, and some of the most recent therapeutic approaches in cardiovascular disease. Data Sources: MEDLINE search for English-language articles on thrombosis and atherosclerosis published up to January 2000. Abstracts of recent international meetings on new aspects of thrombus formation and new therapeutic options were reviewed, and references from identified articles were selected and reviewed. Study Selection: Experimental, basic, clinical, and epidemiologic studies related to the pathophysiology of thrombosis on atherosclerotic lesions. Therapeutic approaches were obtained from experimental studies and large clinical investigations. Data Extraction: Arterial vessel wall substrate, theologic conditions, and blood thrombogenicity influence the process of thrombus formation in arteries. Thrombus formation on disrupted atherosclerotic plaques or arterial erosions frequently causes acute coronary syndromes. Severe atherosclerosis of the aorta has been identified as an important morphologic indicator of an increased risk for thromboembolism. Current antithrombotic therapies available as long-term treatment for patients with cardiovascular disease are often not effective enough to prevent acute thrombotic events and deterioration of atherosclerosis. Data Synthesis: Improved understanding of the pathophysiology of thrombus formation on atherosclerotic plaques has led to the development of new therapeutic approaches. Glycoprotein llb/llla, tissue factor, factor Xa, and thrombin inhibitors as well as combined antithrombotic therapy, such as aspirin plus a thienopyridine plus warfarin, are being evaluated as new possible options for the treatment of arterial thrombosis. Conclusions: Long-term treatment with potent antithrombotic drugs, such as tissue factor or factor Xa inhibitors, that effectively block thrombosis without causing bleeding complications could help reduce death from cardiovascular disease.
引用
收藏
页码:224 / 238
页数:15
相关论文
共 175 条
  • [31] 2-0
  • [32] Noninvasive detection of atherosclerosis
    Celermajer, DS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (27) : 2014 - 2015
  • [33] Endothelial dysfunction: Does it matter? Is it reversible?
    Celermajer, DS
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (02) : 325 - 333
  • [34] COAGULATION ACTIVATION IN DIABETES-MELLITUS - THE ROLE OF HYPERGLYCEMIA AND THERAPEUTIC PROSPECTS
    CERIELLO, A
    [J]. DIABETOLOGIA, 1993, 36 (11) : 1119 - 1125
  • [35] Chesebro JH, 1997, HAEMOSTASIS, V27, P12
  • [36] COMBINATION ANTITHROMBOTIC THERAPY IN UNSTABLE REST ANGINA AND NON-Q-WAVE INFARCTION IN NONPRIOR ASPIRIN USERS - PRIMARY END-POINTS ANALYSIS FROM THE ATACS TRIAL
    COHEN, M
    ADAMS, PC
    PARRY, G
    XIONG, J
    CHAMBERLAIN, D
    WIECZOREK, I
    FOX, KAA
    CHESEBRO, JH
    STRAIN, J
    KELLER, C
    KELLY, A
    LANCASTER, G
    ALI, J
    KRONMAL, R
    FUSTER, V
    [J]. CIRCULATION, 1994, 89 (01) : 81 - 88
  • [37] Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
    Coller, BS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) : 1467 - 1471
  • [38] Coller BS, 1998, CIRCULATION, V97, P4
  • [39] TISSUE FACTOR PATHWAY INHIBITOR REDUCES MORTALITY FROM ESCHERICHIA-COLI SEPTIC SHOCK
    CREASEY, AA
    CHANG, ACK
    FEIGEN, L
    WUN, TC
    TAYLOR, FB
    HINSHAW, LB
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (06) : 2850 - 2860
  • [40] CRONENWETT JL, 1984, ARCH SURG-CHICAGO, V119, P430